March 3, 2026Open Access

Eligibility for biological treatments in COPD patients experiencing a severe COPD exacerbation

Key Points

Only a minority of hospitalized COPD patients would qualify for biologic therapy, highlighting treatment access issues.
With only a small percentage eligible, disease phenotyping plays a crucial role in identifying those who can benefit from biologics.
The analysis underscores the importance of optimizing medical treatment, including inhaled medications, before considering biologic therapy.
Implications of this limitation suggest that comprehensive treatment plans are necessary to improve patient outcomes in exacerbations.

Abstract

Only a minority of patients hospitalized due to severe COPD exacerbation would have been eligible to receive biologic therapy. Optimization of medical treatment including inhaled medication in addition to disease phenotyping are pivotal for the recognition of the patients which will benefit from the use of biologics.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Stavroula Zaneli

Agamemnon Bakakos

Κonstantinos Bartziokas

Journals

Respiratory Medicine

Actions

Institutions

Medical University of Vienna

National and Kapodistrian University of Athens

Sotiria General Hospital

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Eligibility for biological treatments in COPD patients experiencing a severe COPD exacerbation

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study